Vectus Biosystems Limited Vectus Biosystems Limited

Vectus Biosystems Limited

VBS

Rank in Stocks #32116
Vectus Biosystems Limited, an Australian medical research and development firm,... Vectus Biosystems Limited, an Australian medical research and development firm, specializes in devising therapies for fibrotic conditions and hypertension. Its pharmaceutical pipeline addresses ailments affecting the heart, kidneys, liver, and lungs. The company's leading experimental drug, VB0004, aims to counter the degradation of functional tissue resulting from fibrosis, scarring, and elevated blood pressure. Furthermore, Vectus intends to advance treatments for hepatic fibrotic diseases, such as non-alcoholic steatohepatitis, and various pulmonary fibrotic disorders. Beyond its therapeutic endeavors, the company also provides AccuCal and RealCount software, tools engineered to enhance the swiftness and precision of DNA and RNA quantification in laboratory settings. Established in 2005, Vectus Biosystems is headquartered in Rosebery, Australia.
Share Price
$0.03592553
Last synced: 2026-11-16
Market Cap
$1.94M
Change (1 day)
-0.39%
Change (1 year)
-71.45%
Country

Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this

Category

Healthcare
Operating Margin for Vectus Biosystems Limited (VBS)
Operating Margin as of November 2026 TTM: 0.00%
According to Vectus Biosystems Limited's latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of -352.95%.
Operating Margin history for Vectus Biosystems Limited from 2012 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
2026 (TTM) 0.00% -100.00%
2025 -352.95% 77.00%
2024 -199.41% -41.25%
2023 -339.44% -4.07%
2022 -353.85% -99.98%
2021 -2,113,772.22% 39,757.60%
2020 -5,303.31% -99.51%
2019 -1,078,763.64% 393.37%
2018 -218,652.98% 2,139.88%
2017 -9,761.81% 82.17%
2016 -5,358.54% -93.43%
2015 -81,532.50% 48,058.59%
2014 -169.30% -11.28%
2013 -190.83% 0.00%
2012 0.00% 0.00%
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
33.87% -
US
-116.04% -
US
25.57% -
AU
29.35% -
NL
31.23% -
BE
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.

Questions about Vectus Biosystems Limited's operating margin

What was Vectus Biosystems Limited's operating margin in 2025?

In 2025, Vectus Biosystems Limited's operating margin was -352.95%, compared with -199.41% in 2024.

How has Vectus Biosystems Limited's operating margin changed since 2020?

From 2020 to 2025, Vectus Biosystems Limited's operating margin was highest in 2024 (-199.41%) and lowest in 2021 (-2,113,772.22%).

How does Vectus Biosystems Limited's operating margin compare with similar companies?

Vectus Biosystems Limited's operating margin (0.00%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 33.87%.